Allergic Conjunctivitis Market, By Type (Bacterial, Allergic, Viral, and Chemical), By Drug Class (Antibiotics, Mast Cell Stabilizers, Steroids, and Others), By End Users (Hospitals and Clinics and Specialty Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2029

Allergic conjunctivitis is an eye fixed inflammation caused by an allergy because of allergens like pollen or mold spores, dust mites and animal fur. The eyeball features a membrane called conjunctiva which is vulnerable to irritation from allergens. Allergic conjunctivitis is that the body’s reaction to substances which are potentially harmful. There are differing types of allergic conjunctivitis like seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis and atopic kerato conjunctivitis. A number of the symptoms of allergic conjunctivitis are red, itchy, watery and burning eyes. Allergic conjunctivitis is often treated by oral medications, eye drops or immunotherapy.

The Allergic Conjunctivitis Market accounted for US$ 2.6 billion in 2020 and is estimated to be US$ 4.2 billion by 2029 and is anticipated to register a CAGR of 5.3%.

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the product segment. Government across the countries has imposed strict lockdown to limit the spread of disease. The pandemic has hugely impacted the pharmaceutical sectors due strong decline in the hospital visits as per the government’s norms and condition. This is especially critical for the drugs market as several non-essential and non-critical medical procedures have been postponed in light of the pandemic. This report will quantify the impact of pandemic on allergic conjunctivitis market.

The global allergic conjunctivitis treatment market is also driven by rise in air pollution in major cities across the globe. A research study published in 2016 by the National Center for Biotechnology Information (NCBI) revealed that ambient air pollution and weather changes are responsible for the occurrence as well as worsening of allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of conjunctiva with the outside environment. Hence, rise in air pollution propels the global allergic conjunctivitis treatment market.

Development of new treatment options

Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC’s EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors fuel the growth of the global allergic conjunctivitis treatment market. Furthermore, factors such as appropriate diagnosis for viral conjunctivitis and limited awareness regarding advanced technologies are hampering the growth of the global market.

The global allergic conjunctivitis market is segmented based on type, drug class, end 

On the basis of type, the global allergic conjunctivitis market is segmented into bacterial, allergic, viral, and chemical. Based on drug class, the target market is segmented into antibiotics, mast cell stabilizers, steroids, and others. Based on end user, the target market segmented into hospitals and clinics and specialty centers.

On region the global allergic conjunctivitis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for allergic conjunctivitis treatments due to high prevalence of allergic conjunctivitis. According to the American Society of Cataract and Refractive Surgery (ASCRS), around 50 million to 60 million people in the U.S. had allergic conjunctivitis in 2015. Moreover, the allergic conjunctivitis treatment market in Asia Pacific is expected to grow at a rapid pace due to large population base leading to increase in demand for improved health care facilities.

Allergic Conjunctivitis Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global allergic conjunctivitis market report based on type, drug class, end user and region.

Allergic Conjunctivitis Market, By Type:

• Bacterial
• Allergic
• Viral
• Chemical

Allergic Conjunctivitis Market, By Drug Class:

• Antibiotics
• Mast Cell Stabilizers
• Steroids
• others

Allergic Conjunctivitis Market, By End User:

• Hospitals and Clinics
• Specialty Centers

Allergic Conjunctivitis Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the global allergic conjunctivitis market includes Akorn Incorporated, Allergan, Bausch Health Companies, Inc., Novartis AG, Santen Pharmaceutical Co. Ltd., Sun Pharma Advanced Research Company Ltd., Ocular Therapeutix, Inc., Sirion Therapeutics, Inc., Boehringer Ingelheim International GmbH, Atopix Therapeutics Ltd., and Auven Therapeutics. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, in April 2020, Alembic Pharmaceuticals Limited announced that the company had received an abbreviated new drug application (ANDA) approval from the FDA for their generic ophthalmic solution of alcaftadine for the disease indication of allergic conjunctivitis.

• Akorn Incorporated
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Allergan
• Bausch Health Companies, Inc.
• Novartis AG
• Santen Pharmaceutical Co. Ltd.
• Sun Pharma Advanced Research Company Ltd.
• Ocular Therapeutix, Inc.
• Sirion Therapeutics, Inc.
• Boehringer Ingelheim International GmbH
• Atopix Therapeutics Ltd.
• Auven Therapeutics